Dipartimento Diagnostica per Immagini e Radioterapia Seconda Università di Napoli-P.zza Luigi Miraglia-(80138) Napoli, Italy.
Radiat Oncol. 2012 Jan 30;7:12. doi: 10.1186/1748-717X-7-12.
This is an observational study and the aim is to evaluate the effect of dietary supplements based on Resveratrol, Lycopene, Vitamin C and Anthocyanins (Ixor®) in reducing skin toxicity due to external beam radiotherapy in patients affected by breast cancer.
71 patients were enrolled and they were divided in two different groups: a control group (CG) of 41 patients treated with prophylactic topical therapy based on hyaluronic acid and topical steroid therapy in case of occurrence of radiodermatitis, and a Ixor-Group (IG) of 30 patients treated also with an oral therapy based on Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor®) at a dose of 2 tablets/day, starting from 10 days before the radiation treatment until 10 days after the end of treatment. Skin toxicity has been related to PTV, to breast volume that received a radiation dose equal or lower than 107%, included between 107% and 110%, or greater than 110% of the prescribed dose. Moreover it's been studied the relationship between skin toxicity and the chemotherapy schedule used before treatment. We calculated in both groups the percentage of patients who had a skin toxicity of grade 2 or 3 (according to RTOG scale). Absolute risk reduction (ARR), relative risk (RR) and odds ratio (OR) have been calculated for each relationship.
Control Group (CG) patients with a PTV > 500 ml presented skin toxicity G2 + G3 in 30% of cases, versus 25% of Ixor-Group (IG) [OR 0.77]. In patients with a PTV < 500 ml G2 + G3 toxicity was 0% in the IG compared to 18% in CG (OR 0.23). When Dmax was less than or equal to 107% of the prescribed dose skin toxicity was G2 + G3 in 12.5% in CG, versus 0% in IG (OR 0.73), instead when Dmax was included between 107 and 110% of the prescribed dose, G2 + G3 skin toxicity was 35% in CG and 21% in IG (OR 0.50). In patients undergoing chemotherapy with anthracyclines and taxanes, G2 + G3 toxicity was 27% in CG, against 20% in IG (OR 0.68).
The protective effect of Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor®) is more detected in patients with PTV < 500 ml, when Dmax reaches values lower or equal to 107%, but not exceeding 110% of the prescribed dose, and in patients undergoing adjuvant chemotherapy with anthracyclines and taxanes.
这是一项观察性研究,目的是评估基于白藜芦醇、番茄红素、维生素 C 和花青素(Ixor®)的膳食补充剂在减少乳腺癌患者接受外部束放射治疗引起的皮肤毒性方面的效果。
共纳入 71 名患者,将其分为两组:对照组(CG)41 例,接受基于透明质酸的预防性局部治疗和发生放射性皮炎时的局部皮质类固醇治疗;Ixor 组(IG)30 例,还接受基于白藜芦醇、番茄红素、维生素 C 和花青素(Ixor®)的口服治疗,剂量为每天 2 片,从放射治疗前 10 天开始,持续到治疗结束后 10 天。皮肤毒性与 PTV、接受剂量等于或低于 107%、107%至 110%或高于 110%规定剂量的乳房体积相关。此外,还研究了皮肤毒性与治疗前使用的化疗方案之间的关系。我们在两组中计算了发生 2 级或 3 级皮肤毒性(根据 RTOG 量表)的患者比例。为每个关系计算了绝对风险降低(ARR)、相对风险(RR)和比值比(OR)。
PTV > 500 ml 的 CG 组患者皮肤毒性 G2 + G3 发生率为 30%,而 IG 组为 25%[OR 0.77]。PTV < 500 ml 的患者 IG 组 G2 + G3 毒性发生率为 0%,CG 组为 18%[OR 0.23]。当 Dmax 等于或小于规定剂量的 107%时,CG 组皮肤毒性 G2 + G3 发生率为 12.5%,IG 组为 0%[OR 0.73],而当 Dmax 为 107%至 110%规定剂量时,CG 组 G2 + G3 皮肤毒性发生率为 35%,IG 组为 21%[OR 0.50]。接受蒽环类和紫杉类化疗的患者,CG 组 G2 + G3 毒性发生率为 27%,IG 组为 20%[OR 0.68]。
白藜芦醇、番茄红素、维生素 C 和花青素(Ixor®)的保护作用在 PTV < 500 ml、Dmax 达到或低于 107%但不超过 110%规定剂量的患者中更明显,并且在接受蒽环类和紫杉类辅助化疗的患者中更明显。